[Preparation and antitumor activity characterization of oncolytic nanoparticles encapsulating CVA21].
This study aims to investigate the potential of oncolytic nanoparticles encapsulating Coxsackievirus A21 (CVA21) full-genome mRNA (CVA21@ONP) to resurrect CVA21 and induce apoptosis in host cells, as well as the antitumor immune effects of CVA21@ONP in immunocompetent tumor-bearing BALB/c mice. We used lipid nanoparticles (LNPs) to encapsulate CVA21 full-genome mRNA, thus preparing CVA21@ONP. The killing efficacy of CVA21@ONP was determined by the plaque assay and cell counting kit-8 (CCK-8), and the apoptosis in HT29 and CT26-iRFP cells was evaluated by flow cytometry. Mice were administrated with CVA21@ONP at high and low doses intratumorally, and the growth of tumors expressing infra-red fluorescent protein (iRFP) was monitored. Additionally, the types and changes of immune cells in the spleen were analyzed by flow cytometry. The results demonstrated that CVA21@ONP successfully resurrected CVA21 in both HT29 and U87MG cells. The plaque assay revealed robust killing effects of CVA21@ONP against both human and murine cell lines, and flow cytometry results showed increased early and late apoptotic cells. Notably, intratumoral detection revealed significantly down-regulated expression of iRFP in both high- and low-dose CVA21@ONP groups. Flow cytometry results further indicated that CVA21@ONP treatment effectively reduced the levels of immunosuppressive cells, including myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), in the spleen, while enhancing T cell-dependent antitumor immune responses. These findings suggest that CVA21@ONP can replicate and survive extensively both <i>in vitro</i> and <i>in vivo</i>, activating the immune system of mice administrated with CVA21@ONP to target cells at the tumor site, thereby remodeling the tumor immune microenvironment and accelerating the suppression or even complete regression of tumors. The oncolytic performance of CVA21@ONP has been verified through intratumoral injection administration in this study, aimed at further exploring its therapeutic potential and promoting the development of the field of tumor treatment.
Authors
- Yinping Wang (ORCID: https://orcid.org/0000-0002-1267-2205)
- Linkang Cai (ORCID: https://orcid.org/0000-0002-8827-8386)
- Binlei Liu (ORCID: https://orcid.org/0000-0001-6210-1585)
- Jingjing Zhou (ORCID: https://orcid.org/0000-0002-6049-3201)
- Qiying Cai
- Xiaodi Zheng (ORCID: https://orcid.org/0000-0001-6957-5505)
- Yang Wang (ORCID: https://orcid.org/0000-0002-5040-2492)
Institutions
- Hubei University of Science and Technology (CN)
- Nanjing Medical University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- PubMed
- Published
- 2025-04-25
- DOI
- https://doi.org/10.13345/j.cjb.240690
- Primary Topic
- Cancer Research and Treatments
- Type
- article